Onur H - Search Results

1

Nine weeks versus 1 year adjuvant trastuzumab in patients with early breast cancer: an observational study by the Turkish Oncology Group (TOG).

İçli F, Altundağ K, Akbulut H, Paydaş S, Başaran G, Saip P, Doğu GG, Eralp Y, Uslu R, Sevinç A, Onur H, Mandel NM, Sezgin C, Altınbaş M, Güler N, Işıkdoğan A, Gökmen E, Uygun K, Üstüner Z, Yaren A, Demirkan B, Coşkun U, Ata A, Özkan M, Arican A. İçli F, et al. Among authors: onur h. Breast Cancer. 2015 Sep;22(5):480-5. doi: 10.1007/s12282-013-0506-y. Epub 2013 Dec 12. Breast Cancer. 2015. PMID: 24338610

2

Phase II study of lapatinib in combination with vinorelbine in patients with HER2 positive recurrent or metastatic breast cancer: a multicentric Turkish Oncology Group (TOG) trial.

Saip P, Eralp Y, Sen F, Karaca H, Ozkan M, Cetin B, Benekli M, Kucukoner M, Isikdogan A, Un O, Basaran G, Onur H. Saip P, et al. Among authors: onur h. Breast. 2013 Oct;22(5):628-33. doi: 10.1016/j.breast.2013.07.048. Epub 2013 Aug 16. Breast. 2013. PMID: 23954396 Clinical Trial.

3

Adjuvant oral etoposide plus cisplatin (EoP) following sequential doxorubicin/cyclophosphamide (AC) and docetaxel (T) in early breast cancer patients with 4 or more positive lymph nodes (10 years follow-up).

Icli F, Akbulut H, Onur H, Yalcin B, Demirkazık A, Senler FÇ. Icli F, et al. Among authors: onur h. Breast. 2011 Apr;20(2):155-7. doi: 10.1016/j.breast.2010.09.002. Epub 2010 Oct 15. Breast. 2011. PMID: 20951586 Free article.

4

Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancer.

Icli F, Akbulut H, Utkan G, Yalcin B, Dincol D, Isikdogan A, Demirkazik A, Onur H, Cay F, Büyükcelik A. Icli F, et al. Among authors: onur h. J Surg Oncol. 2007 May 1;95(6):507-12. doi: 10.1002/jso.20728. J Surg Oncol. 2007. PMID: 17192920 Clinical Trial.

5

Long-term outcome of mesna, ifosfamide, mitoxantrone, etoposide (MINE) regimen as a consolidation in patients with aggressive non-Hodgkin lymphoma responding to CHOP.

Dincol D, Buyukcelik A, Dogan M, Akbulut H, Samur M, Demirkazik A, Senler FC, Onur H, Icli F. Dincol D, et al. Among authors: onur h. Med Oncol. 2010 Sep;27(3):942-5. doi: 10.1007/s12032-009-9313-x. Epub 2009 Sep 29. Med Oncol. 2010. PMID: 19787462 Clinical Trial.

6

The Outcome of Patients with Triple Negative Breast Cancer: The Turkish Oncology Group Experience.

Eralp Y, Kılıç L, Alço G, Başaran G, Doğan M, Dinçol D, Demirci S, İçli F, Onur H, Saip P, Haydaroğlu A. Eralp Y, et al. Among authors: onur h. J Breast Health. 2014 Oct 1;10(4):209-215. doi: 10.5152/tjbh.2014.1904. eCollection 2014 Oct. J Breast Health. 2014. PMID: 28331673 Free PMC article.

7

A randomized trial of four cycles of adjuvant AC (adriamycin + cyclophosphamide) +/- two cycles of EP (etoposide + cisplatin) in node positive patients with breast cancer.

Içli F, Akbulut H, Dinçol D, Onur H, Demirkazik A, Cam R, Cay F, Demirci S, Uner A, Erekul S. Içli F, et al. Among authors: onur h. Ann Oncol. 2001 Jul;12(7):1011-3. doi: 10.1023/a:1011118004629. Ann Oncol. 2001. PMID: 11521785 Free article. Clinical Trial.

8

Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: a randomised phase III trial of Turkish Oncology Group.

Icli F, Akbulut H, Uner A, Yalcin B, Baltali E, Altinbas M, Coşkun S, Komurcu S, Erkisi M, Demirkazik A, Senler FC, Sencan O, Büyükcelik A, Boruban C, Onur H, Zengin N, Sak SD. Icli F, et al. Among authors: onur h. Br J Cancer. 2005 Feb 28;92(4):639-44. doi: 10.1038/sj.bjc.6602388. Br J Cancer. 2005. PMID: 15726120 Free PMC article. Clinical Trial.

9

The symptomatic benefit (the clinical benefit response) from the second-line chemotherapy in patients with advanced gastric adenocarcinoma.

Sencan O, Buyukcelik A, Yalcin B, Boruban MC, Akbulut H, Demirkazik A, Senler FC, Onur H, Icli F. Sencan O, et al. Among authors: onur h. Eur J Cancer Care (Engl). 2008 Jan;17(1):26-32. doi: 10.1111/j.1365-2354.2007.00798.x. Eur J Cancer Care (Engl). 2008. PMID: 18181888

10

ABO and Rh blood groups frequency in women with HER2 positive breast cancer.

Urun Y, Utkan G, Altundag K, Arslan O, Onur H, Arslan UY, Kocer M, Dogan I, Senler FC, Yalcin B, Demirkazik A, Akbulut H, Icli F. Urun Y, et al. Among authors: onur h. J BUON. 2012 Jul-Sep;17(3):457-60. J BUON. 2012. PMID: 23033281

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

36 results

Search Page